Researchers validate first-ever AI biomarker for ADT benefit in prostate cancer

Data from a new study published in NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer.

from News Medical Medical Research News Feed https://ift.tt/cmvb84T